Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALIBRATE encaleret versus standard of care in autosomal dominant hypocalcemia type 1
jRCT2031230392Phase 3Active, not recruiting
- Sponsor
- Calcilytix Therapeutics
- Start
- Sep 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial in autosomal dominant hypocalcemia type 1 (ADH1) comparing Encaleret with Standard of care (2 arms). Primary endpoint: Responder rate at completion of maintenance dosing period. Started Sep 2023; status: active, not recruiting.
02
Drugs
encaleret
03
Conditions
autosomal dominant hypocalcemia type 1 (ADH1)
Beyond the preview
Go deeper on jRCT2031230392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230392.